Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) CEO Leonard S. Schleifer sold 9,064 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $1,015.43, for a total transaction of $9,203,857.52. Following the sale, the chief executive officer now directly owns 55,134 shares of […]
US Bancorp DE grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,941 shares of the biopharmaceutical company’s stock after acquiring an additional 310 shares during […]
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the sale, the director now directly owns […]
3Chopt Investment Partners LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 599 shares of the biopharmaceutical company’s stock, valued at approximately $526,000. Several other institutional investors and hedge funds have also recently modified their […]
ProVise Management Group LLC increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 3.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,486 shares of the biopharmaceutical company’s stock after purchasing an additional 47 shares during the quarter. […]